(Q43978086)

28 November 2017

Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia (English)

1 reference

28 November 2017

1 reference

1 reference

1 reference

1 reference

9

Sikic BI

1 reference

28 November 2017

Lacayo NJ

1

1 reference

28 November 2017

Lum BL

2

1 reference

28 November 2017

Becton DL

3

1 reference

28 November 2017

Weinstein H

4

1 reference

28 November 2017

Ravindranath Y

5

1 reference

28 November 2017

Chang MN

6

1 reference

28 November 2017

Bomgaars L

7

1 reference

28 November 2017

Lauer SJ

8

1 reference

28 November 2017

Dahl GV

10

1 reference

28 November 2017

1 May 2002

1 reference

28 November 2017

1 reference

28 November 2017

16

1 reference

28 November 2017

5

1 reference

28 November 2017

920-927

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2402455

28 November 2017

0 references

cites work

Charles F. Kettering Prize. P-glycoprotein and resistance to anticancer drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402455

7 January 2021

Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402455

7 January 2021

Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402455

7 January 2021

Reactivity of P-glycoprotein monoclonal antibodies in childhood cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402455

7 January 2021

Multidrug resistance in pediatric oncology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402455

7 January 2021

Assessment of systemic toxicity in children receiving chemotherapy with cyclosporine for sarcoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402455

7 January 2021

Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402455

7 January 2021

Expression of HER2/erbB-2 correlates with survival in osteosarcoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402455

7 January 2021

Prognostic value of rhodamine-efflux and MDR-1/P-170 expression in childhood acute leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402455

7 January 2021

Expression of mdr1, mrp, topoisomerase II alpha/beta, and cyclin A in primary or relapsed states of acute lymphoblastic leukaemias.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402455

7 January 2021

P-glycoprotein and glutathione S-transferase pi in childhood acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402455

7 January 2021

Different types of non-P-glycoprotein mediated multiple drug resistance in children with relapsed acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402455

7 January 2021

P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402455

7 January 2021

Treatment of children with refractory acute lymphocytic leukemia with vincristine and diltiazem.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402455

7 January 2021

Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance: the causative role of improper dissolution of Cremophor EL

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402455

7 January 2021

Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402455

7 January 2021

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402455

7 January 2021

Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402455

7 January 2021

Clinical pharmacodynamics of continuous-infusion etoposide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402455

7 January 2021

Improved high-performance liquid chromatography of the new antineoplastic agents bisantrene and mitoxantrone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402455

7 January 2021

A program package for simulation and parameter estimation in pharmacokinetic systems

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402455

7 January 2021

Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402455

7 January 2021

Pharmacokinetics of VP16-213 given by different administration methods

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402455

7 January 2021

A study of the feasibility and accuracy of pharmacokinetically guided etoposide dosing in children

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402455

7 January 2021

Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402455

7 January 2021

Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402455

7 January 2021

Population pharmacokinetics of mitoxantrone performed by a NONMEM method

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402455

7 January 2021

Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402455

7 January 2021

Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402455

7 January 2021

High-dose cyclosporin with etoposide--toxicity and pharmacokinetic interaction in children with solid tumours

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402455

7 January 2021

Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402455

7 January 2021

Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402455

7 January 2021

Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402455

7 January 2021

Alteration of the daunorubicin-triggered sphingomyelin-ceramide pathway and apoptosis in MDR cells: influence of drug transport abnormalities.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402455

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2402455

1 reference

Dimensions Publication ID

28 November 2017

0 references

1 reference